Prof Constantine Tam
Honorary Clinical Professor
Department of Medicine
936 Scholarly works
7 Projects
HIGHLIGHTS
2022
Journal article
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
DOI: 10.1182/blood.20220160402022
Journal article
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
DOI: 10.1182/bloodadvances.20220083252022
Journal article
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
DOI: 10.1182/blood.20210127752022
Journal article
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
DOI: 10.1182/bloodadvances.20210056212022
Research grants (ARC, NHMRC, MRFF)
Understanding and Averting Blood Cancer Resistance to Therapy
2019
Research grants (ARC, NHMRC, MRFF)
The Aim2 Study: Genomically Guided Novel Combination Treatment of Mantle Cell Lymphoma
2017
Research Grant
Centre of Research Excellence in Chronic Lymphotic Leukemia at the Victorian Comprehensive Cancer Centre
RECENT SCHOLARLY WORKS
2026
Journal article
First-line treatment for CLL in the era of targeted therapy
DOI: 10.1038/s41408-025-01434-22026
Journal article
Differential perforin sensitivity drives lineage-dependent resistance to CAR T-cell killing in blood cancer cell lines
DOI: 10.1182/bloodadvances.20260198812026
Journal article
First-line ibrutinib plus venetoclax for nonblastoid mantle cell lymphoma in patients ≥65 years old or with TP53 mutations
DOI: 10.1182/blood.20250328332026
Journal article
Patient-reported symptom burden after chimeric antigen receptor T-cell therapy.
DOI: 10.1111/bjh.708422026
Journal article
Association between patient-reported symptoms and clinical outcomes in R/R CLL.
DOI: 10.1182/bloodadvances.20260204052026
Journal article
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma
DOI: 10.1182/bloodadvances.20260201232026
Journal article
Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up
DOI: 10.1007/s12325-026-03661-w2026
Journal article
Richter transformation: emerging immunologic strategies beyond chemoimmunotherapy.
DOI: 10.1182/bloodadvances.2026020197